According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
Several other equities analysts also recently issued reports on the stock. Jefferies Group boosted their price target on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a hold rating in a report on Friday, August 5th. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the company a buy rating in a report on Thursday, July 21st. Finally, Leerink Swann started coverage on shares of Aquinox Pharmaceuticals in a report on Tuesday, October 4th. They set an outperform rating and a $24.00 price target for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $20.00.
Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 13.56 on Tuesday. The firm’s 50-day moving average is $12.45 and its 200 day moving average is $9.17. The stock’s market capitalization is $233.39 million. Aquinox Pharmaceuticals has a 12-month low of $6.01 and a 12-month high of $16.75.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.22. Equities research analysts anticipate that Aquinox Pharmaceuticals will post ($2.23) earnings per share for the current year.
In related news, major shareholder Bros. Advisors Lp Baker acquired 2,783,605 shares of Aquinox Pharmaceuticals stock in a transaction that occurred on Tuesday, September 20th. The stock was acquired at an average price of $12.25 per share, with a total value of $34,099,161.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of AQXP. Boxer Capital LLC increased its stake in Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock valued at $5,811,000 after buying an additional 57,738 shares during the last quarter. Bridgeway Capital Management Inc. increased its stake in Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock valued at $410,000 after buying an additional 50,000 shares during the last quarter. Opaleye Management Inc. bought a new stake in Aquinox Pharmaceuticals during the second quarter valued at $1,953,000. BlackRock Fund Advisors increased its stake in Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock valued at $1,514,000 after buying an additional 3,977 shares during the last quarter. Finally, BlackRock Advisors LLC increased its stake in Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock valued at $2,678,000 after buying an additional 8,280 shares during the last quarter. 65.87% of the stock is owned by institutional investors and hedge funds.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.